Stockreport

Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP

Emergent Biosolutions, Inc.  (EBS) 
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm Check Earnings Report
US:NYSE Investor Relations: investors.emergentbiosolutions.com
PDF GAITHERSBURG, Md., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study eva [Read more]